Favorable role of IDH 1/2 mutations aided with MGMT promoter gene methylation in the outcome of patients with malignant glioma

Favorable role of IDH 1/2 mutations aided with MGMT promoter gene methylation in the outcome of patients with malignant glioma

The implications of molecular biomarkers 1/2 mutations and gene promoter methylation were evaluated for prognostic outcome of glioma patients. Glioma cases were analyzed for 1/2 mutations and promoter methylation by DNA sequencing and methylation-specific PCR, respectively. Mutations found in 1/2 ge...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Future science OA 2021-03, Vol.7 (3), p.FSO663
Hauptverfasser: Pandith, Arshad A, Qasim, Iqbal, Baba, Shahid M, Koul, Aabid, Zahoor, Wani, Afroze, Dil, Lateef, Adil, Manzoor, Usma, Bhat, Ina A, Sanadhya, Dheera, Bhat, Abdul R, Ramzan, Altaf U, Mohammad, Fozia, Anwar, Iqra
Format: Artikel
Sprache:eng
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue 3
container_start_page FSO663
container_title Future science OA
container_volume 7
creator Pandith, Arshad A
Qasim, Iqbal
Baba, Shahid M
Koul, Aabid
Zahoor, Wani
Afroze, Dil
Lateef, Adil
Manzoor, Usma
Bhat, Ina A
Sanadhya, Dheera
Bhat, Abdul R
Ramzan, Altaf U
Mohammad, Fozia
Anwar, Iqra
description The implications of molecular biomarkers 1/2 mutations and gene promoter methylation were evaluated for prognostic outcome of glioma patients. Glioma cases were analyzed for 1/2 mutations and promoter methylation by DNA sequencing and methylation-specific PCR, respectively. Mutations found in 1/2 genes totaled 63.4% (N = 40) wherein 1 mutations were significantly associated with oligidendrioglioma (p = 0.005) and astrocytoma (p = 0.0002). 1 mutants presented more, 60.5% in promoter-methylated cases (p = 0.03). 1 mutant cases had better survival for glioblastoma and oligodendrioglioma (log-rank p = 0.01). Multivariate analysis confirmed better survival in methylation carriers (hazard ratio [HR]: 0.59; p = 0.031). Combination of both biomarkers showed better prognosis on temozolomide (p 
doi_str_mv 10.2144/fsoa-2020-0057
format Article
fullrecord <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_2144_fsoa_2020_0057</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>33552543</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1073-ec5daf799a2892bbb59a205a66d72c897f56a8a3a6a1586266647fd28b40bd713</originalsourceid><addsrcrecordid>eNpNkMtOwzAQRS0EolXpliXyD4T6ETvJEhX6kFqxKetokjhtUBxHtgvqhm_HaQGxmYfm3ivNQeiekkdG43hWOwMRI4xEhIjkCo0ZETISkvHrf_MITZ17J4TQsEmW3qIR50IwEfMx-lrAh7FQtApbE4qp8fp5hemMYX304BvTOQxNpSr82fgD3i63O9xbo41XFu9Vp7BW_nBqz1LcdNgfQsrRl0af0_pwUJ13F7uGttl30Hm8bxuj4Q7d1NA6Nf3pE_S2eNnNV9HmdbmeP22ikpKER6oUFdRJlgFLM1YUhQgTESBllbAyzZJaSEiBgwQq0vCllHFSVywtYlJUCeUT9HjJLa1xzqo6722jwZ5ySvKBZT6wzAeW-cAyGB4uhv5YaFX9yX_J8W-LdXBU</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Favorable role of IDH 1/2 mutations aided with MGMT promoter gene methylation in the outcome of patients with malignant glioma</title><source>Taylor &amp; Francis Open Access</source><source>DOAJ Directory of Open Access Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>PubMed Central Open Access</source><creator>Pandith, Arshad A ; Qasim, Iqbal ; Baba, Shahid M ; Koul, Aabid ; Zahoor, Wani ; Afroze, Dil ; Lateef, Adil ; Manzoor, Usma ; Bhat, Ina A ; Sanadhya, Dheera ; Bhat, Abdul R ; Ramzan, Altaf U ; Mohammad, Fozia ; Anwar, Iqra</creator><creatorcontrib>Pandith, Arshad A ; Qasim, Iqbal ; Baba, Shahid M ; Koul, Aabid ; Zahoor, Wani ; Afroze, Dil ; Lateef, Adil ; Manzoor, Usma ; Bhat, Ina A ; Sanadhya, Dheera ; Bhat, Abdul R ; Ramzan, Altaf U ; Mohammad, Fozia ; Anwar, Iqra</creatorcontrib><description>The implications of molecular biomarkers 1/2 mutations and gene promoter methylation were evaluated for prognostic outcome of glioma patients. Glioma cases were analyzed for 1/2 mutations and promoter methylation by DNA sequencing and methylation-specific PCR, respectively. Mutations found in 1/2 genes totaled 63.4% (N = 40) wherein 1 mutations were significantly associated with oligidendrioglioma (p = 0.005) and astrocytoma (p = 0.0002). 1 mutants presented more, 60.5% in promoter-methylated cases (p = 0.03). 1 mutant cases had better survival for glioblastoma and oligodendrioglioma (log-rank p = 0.01). Multivariate analysis confirmed better survival in methylation carriers (hazard ratio [HR]: 0.59; p = 0.031). Combination of both biomarkers showed better prognosis on temozolomide (p &lt; 0.05). 1/2 mutations proved independent prognostic factors in glioma and associated with methylation for better survival.</description><identifier>ISSN: 2056-5623</identifier><identifier>EISSN: 2056-5623</identifier><identifier>DOI: 10.2144/fsoa-2020-0057</identifier><identifier>PMID: 33552543</identifier><language>eng</language><publisher>England</publisher><ispartof>Future science OA, 2021-03, Vol.7 (3), p.FSO663</ispartof><rights>2020 Arshad A. Pandith.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c1073-ec5daf799a2892bbb59a205a66d72c897f56a8a3a6a1586266647fd28b40bd713</citedby><cites>FETCH-LOGICAL-c1073-ec5daf799a2892bbb59a205a66d72c897f56a8a3a6a1586266647fd28b40bd713</cites><orcidid>0000-0002-7912-2638</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,860,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33552543$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Pandith, Arshad A</creatorcontrib><creatorcontrib>Qasim, Iqbal</creatorcontrib><creatorcontrib>Baba, Shahid M</creatorcontrib><creatorcontrib>Koul, Aabid</creatorcontrib><creatorcontrib>Zahoor, Wani</creatorcontrib><creatorcontrib>Afroze, Dil</creatorcontrib><creatorcontrib>Lateef, Adil</creatorcontrib><creatorcontrib>Manzoor, Usma</creatorcontrib><creatorcontrib>Bhat, Ina A</creatorcontrib><creatorcontrib>Sanadhya, Dheera</creatorcontrib><creatorcontrib>Bhat, Abdul R</creatorcontrib><creatorcontrib>Ramzan, Altaf U</creatorcontrib><creatorcontrib>Mohammad, Fozia</creatorcontrib><creatorcontrib>Anwar, Iqra</creatorcontrib><title>Favorable role of IDH 1/2 mutations aided with MGMT promoter gene methylation in the outcome of patients with malignant glioma</title><title>Future science OA</title><addtitle>Future Sci OA</addtitle><description>The implications of molecular biomarkers 1/2 mutations and gene promoter methylation were evaluated for prognostic outcome of glioma patients. Glioma cases were analyzed for 1/2 mutations and promoter methylation by DNA sequencing and methylation-specific PCR, respectively. Mutations found in 1/2 genes totaled 63.4% (N = 40) wherein 1 mutations were significantly associated with oligidendrioglioma (p = 0.005) and astrocytoma (p = 0.0002). 1 mutants presented more, 60.5% in promoter-methylated cases (p = 0.03). 1 mutant cases had better survival for glioblastoma and oligodendrioglioma (log-rank p = 0.01). Multivariate analysis confirmed better survival in methylation carriers (hazard ratio [HR]: 0.59; p = 0.031). Combination of both biomarkers showed better prognosis on temozolomide (p &lt; 0.05). 1/2 mutations proved independent prognostic factors in glioma and associated with methylation for better survival.</description><issn>2056-5623</issn><issn>2056-5623</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNpNkMtOwzAQRS0EolXpliXyD4T6ETvJEhX6kFqxKetokjhtUBxHtgvqhm_HaQGxmYfm3ivNQeiekkdG43hWOwMRI4xEhIjkCo0ZETISkvHrf_MITZ17J4TQsEmW3qIR50IwEfMx-lrAh7FQtApbE4qp8fp5hemMYX304BvTOQxNpSr82fgD3i63O9xbo41XFu9Vp7BW_nBqz1LcdNgfQsrRl0af0_pwUJ13F7uGttl30Hm8bxuj4Q7d1NA6Nf3pE_S2eNnNV9HmdbmeP22ikpKER6oUFdRJlgFLM1YUhQgTESBllbAyzZJaSEiBgwQq0vCllHFSVywtYlJUCeUT9HjJLa1xzqo6722jwZ5ySvKBZT6wzAeW-cAyGB4uhv5YaFX9yX_J8W-LdXBU</recordid><startdate>202103</startdate><enddate>202103</enddate><creator>Pandith, Arshad A</creator><creator>Qasim, Iqbal</creator><creator>Baba, Shahid M</creator><creator>Koul, Aabid</creator><creator>Zahoor, Wani</creator><creator>Afroze, Dil</creator><creator>Lateef, Adil</creator><creator>Manzoor, Usma</creator><creator>Bhat, Ina A</creator><creator>Sanadhya, Dheera</creator><creator>Bhat, Abdul R</creator><creator>Ramzan, Altaf U</creator><creator>Mohammad, Fozia</creator><creator>Anwar, Iqra</creator><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><orcidid>https://orcid.org/0000-0002-7912-2638</orcidid></search><sort><creationdate>202103</creationdate><title>Favorable role of IDH 1/2 mutations aided with MGMT promoter gene methylation in the outcome of patients with malignant glioma</title><author>Pandith, Arshad A ; Qasim, Iqbal ; Baba, Shahid M ; Koul, Aabid ; Zahoor, Wani ; Afroze, Dil ; Lateef, Adil ; Manzoor, Usma ; Bhat, Ina A ; Sanadhya, Dheera ; Bhat, Abdul R ; Ramzan, Altaf U ; Mohammad, Fozia ; Anwar, Iqra</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1073-ec5daf799a2892bbb59a205a66d72c897f56a8a3a6a1586266647fd28b40bd713</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Pandith, Arshad A</creatorcontrib><creatorcontrib>Qasim, Iqbal</creatorcontrib><creatorcontrib>Baba, Shahid M</creatorcontrib><creatorcontrib>Koul, Aabid</creatorcontrib><creatorcontrib>Zahoor, Wani</creatorcontrib><creatorcontrib>Afroze, Dil</creatorcontrib><creatorcontrib>Lateef, Adil</creatorcontrib><creatorcontrib>Manzoor, Usma</creatorcontrib><creatorcontrib>Bhat, Ina A</creatorcontrib><creatorcontrib>Sanadhya, Dheera</creatorcontrib><creatorcontrib>Bhat, Abdul R</creatorcontrib><creatorcontrib>Ramzan, Altaf U</creatorcontrib><creatorcontrib>Mohammad, Fozia</creatorcontrib><creatorcontrib>Anwar, Iqra</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Future science OA</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Pandith, Arshad A</au><au>Qasim, Iqbal</au><au>Baba, Shahid M</au><au>Koul, Aabid</au><au>Zahoor, Wani</au><au>Afroze, Dil</au><au>Lateef, Adil</au><au>Manzoor, Usma</au><au>Bhat, Ina A</au><au>Sanadhya, Dheera</au><au>Bhat, Abdul R</au><au>Ramzan, Altaf U</au><au>Mohammad, Fozia</au><au>Anwar, Iqra</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Favorable role of IDH 1/2 mutations aided with MGMT promoter gene methylation in the outcome of patients with malignant glioma</atitle><jtitle>Future science OA</jtitle><addtitle>Future Sci OA</addtitle><date>2021-03</date><risdate>2021</risdate><volume>7</volume><issue>3</issue><spage>FSO663</spage><pages>FSO663-</pages><issn>2056-5623</issn><eissn>2056-5623</eissn><abstract>The implications of molecular biomarkers 1/2 mutations and gene promoter methylation were evaluated for prognostic outcome of glioma patients. Glioma cases were analyzed for 1/2 mutations and promoter methylation by DNA sequencing and methylation-specific PCR, respectively. Mutations found in 1/2 genes totaled 63.4% (N = 40) wherein 1 mutations were significantly associated with oligidendrioglioma (p = 0.005) and astrocytoma (p = 0.0002). 1 mutants presented more, 60.5% in promoter-methylated cases (p = 0.03). 1 mutant cases had better survival for glioblastoma and oligodendrioglioma (log-rank p = 0.01). Multivariate analysis confirmed better survival in methylation carriers (hazard ratio [HR]: 0.59; p = 0.031). Combination of both biomarkers showed better prognosis on temozolomide (p &lt; 0.05). 1/2 mutations proved independent prognostic factors in glioma and associated with methylation for better survival.</abstract><cop>England</cop><pmid>33552543</pmid><doi>10.2144/fsoa-2020-0057</doi><orcidid>https://orcid.org/0000-0002-7912-2638</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 2056-5623
ispartof Future science OA, 2021-03, Vol.7 (3), p.FSO663
issn 2056-5623
2056-5623
language eng
recordid cdi_crossref_primary_10_2144_fsoa_2020_0057
source Taylor & Francis Open Access; DOAJ Directory of Open Access Journals; EZB-FREE-00999 freely available EZB journals; PubMed Central; PubMed Central Open Access
title Favorable role of IDH 1/2 mutations aided with MGMT promoter gene methylation in the outcome of patients with malignant glioma
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T00%3A37%3A24IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Favorable%20role%20of%20IDH%201/2%20mutations%20aided%20with%20MGMT%20promoter%20gene%20methylation%20in%20the%20outcome%20of%20patients%20with%20malignant%20glioma&rft.jtitle=Future%20science%20OA&rft.au=Pandith,%20Arshad%20A&rft.date=2021-03&rft.volume=7&rft.issue=3&rft.spage=FSO663&rft.pages=FSO663-&rft.issn=2056-5623&rft.eissn=2056-5623&rft_id=info:doi/10.2144/fsoa-2020-0057&rft_dat=%3Cpubmed_cross%3E33552543%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/33552543&rfr_iscdi=true